Barsax,

I remember looking into the issue of safety of SGLT2is in people with CKD (eGFR<60) and finding that the thinking may have changed.  Perhaps one of our docs can comment.  See:

https://academic.oup.com/ckj/article/13/5/728/5919843

Jupe